Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.46 |
| ▸ | HTR2A | P28223 | 12/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776146 | 0.88 | HTR2C (0.48) | HTR2CHTR2A | |
| SCHEMBL16776130 | 0.88 | HTR2C (0.48) | HTR2CHTR2ARPS6KA3 | |
| SCHEMBL16776226 | 0.88 | HTR2C (0.45) | HTR2CHTR2ARPS6KA3MAPKAPK2 | |
| SCHEMBL16776131 | 0.85 | MCL1 (0.45) | HTR2CHTR2ARPS6KA3MAPKAPK2 | |
| SCHEMBL16776059 | 0.85 | CYP11B2 (0.37) | RPS6KA3 | |
| SCHEMBL16776241 | 0.85 | HTR2C (0.44) | HTR2CHTR2A | |
| SCHEMBL16776243 | 0.85 | RPS6KA3 (0.39) | HTR2CHTR2ARPS6KA3MAPKAPK2 | |
| SCHEMBL16776073 | 0.85 | FGFR4 (0.44) | RPS6KA3 | |
| SCHEMBL16775910 | 0.85 | TSHR (0.48) | HTR2CHTR2ARPS6KA3 | |
| SCHEMBL16776009 | 0.83 | HTR2C (0.45) | HTR2CHTR2ARPS6KA3MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HTR2C 4651/4885HTR2A 4386/4885RPS6KA3 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.